Related Articles
Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
Association between transforming growth factor-β1 expression and the clinical features of triple negative breast cancer
Knockdown of SASS6 reduces growth of MDA‑MB‑231 triple‑negative breast cancer cells through arrest of the cell cycle at the G2/M phase
miR‑1207‑5p regulates the sensitivity of triple‑negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression